ORGANON CANADA - Key Persons

Aaron Falcione - CHRO

Job Titles:

Chief Human Resources Officer
Member of the Executive Leadership Team

As Organon's Chief Human Resources Officer, Aaron Falcione is focused on building a "culture-first" company that attracts the best talent, fosters an environment where all employees have a sense of belonging and can wholeheartedly embrace Organon's values. With diversity, equity and inclusion at the core, Aaron leads a team of Human Resources professionals around the world who are responsible for all aspects of the Organon employee experience, including performance and change management, succession planning, learning and development, and compensation and benefits. Most recently, Aaron served as Vice President, Human Resources at Merck with global responsibility for the commercial organization. He previously led Human Resources for the company's emerging markets and then all markets outside the United States. Prior to Merck, Aaron worked as Vice President of Human Resources for Siemens AG and served in roles of increasing responsibility within PricewaterhouseCoopers' mergers and acquisitions services practice. Aaron received a master's degree in industrial psychology from Kent State University and a bachelor's degree from University of Maryland.

Alan Ezekowitz

Job Titles:

Member of the Audit Committee
Member of the Board of Directors
Member of the Talent Committee

Alan Ezekowitz, M.D., Ph.D., is currently a venture partner at Third Rock Ventures, LLC, a healthcare venture firm, an Entrepreneur in Residence at Cardinal Partners, a venture capital firm, an adviser to Fidelity's Select Biotechnology Portfolio, and as a consultant to H. Lundbeck A/S. From 2011 to 2019, Dr. Ezekowitz was Co-Founder and CEO of Abide Therapeutics, Inc., a biopharmaceutical company acquired by Lundbeck LLC in 2019. Prior to co-founding Abide, he was a Senior Vice President at Merck Research Laboratories responsible for the Bone, Respiratory, Immunology, Inflammation, Endocrine and Dermatology franchises. Prior to his time at Merck, Dr. Ezekowitz was the Chief of Pediatric Services at Partner Healthcare System, Inc. (1999 to 2006) and at the Massachusetts General Hospital (1995-2006). From 2000 to 2006, Dr. Ezekowitz served on the board of directors of Partners Healthcare System, Inc, and from 1995 to 2006, he was the Charles Wilder Professor of Pediatrics at Harvard Medical School and Head of the Laboratory of Developmental Immunology, with over 150 publications in the field of innate immunity. He currently serves on the board of directors of Fulcrum Therapeutics, Inc. (since 2016). Dr. Ezekowitz was born in South Africa, educated at the University of Cape Town in South Africa, and earned his Doctor of Philosophy at the University of Oxford in the United Kingdom.

Amy Cairns

Job Titles:

Executive Director, Women 's Health & Established Brands

Anne Mayrand

Job Titles:

Head, Legal Affairs and Compliance

Carrie S. Cox - Chairman

Job Titles:

Chairman
Chairman of the Audit Committee
Member of the Board of Directors
Chairman of Organon 's Board of Directors

Carrie Cox serves as Chairman of Organon's Board of Directors. Ms. Cox most recently served as Executive Chairman of Humacyte, Inc. until 2019, a then privately-held regenerative medical technology company, where she also held the title of Chief Executive Officer from 2010 to 2018. Ms. Cox served as Executive Vice President of Schering-Plough Corporation and President of Schering-Plough's global pharmaceutical business from 2003 until 2009, when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation's global pharmaceutical business from 1997 until its merger with Pfizer Inc. in 2003. She also currently serves on the board of directors of Texas Instruments Inc. (since 2004), Cardinal Health Inc. (since 2009), and Selecta Biosciences, Inc. (since 2019). She was previously chair of the boards of Array BioPharma, Inc. from 2018 until its acquisition by Pfizer Inc. in 2019, and electroCore, Inc. from 2018 to 2019, and served on the board of directors of Celgene Corp. from 2009 until its acquisition by Bristol-Myers Squibb Co. in 2019. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.

Catherine Brown

Job Titles:

Director, Business Practices & Privacy Officer

Charlotte Owens

Job Titles:

Head of Medical Affairs

Cynthia M. Patton

Job Titles:

Member of the Audit Committee
Member of the Talent Committee
General Counsel and Secretary at Verily Life Sciences

Cynthia M. Patton is currently General Counsel and Secretary at Verily Life Sciences, a healthtech subsidiary of Alphabet Inc., where she oversees the compliance, privacy, security, legal and governmental affairs functions of the company. Prior to Verily, she served as Senior Vice President and Chief Compliance Officer at Amgen Inc. from 2012 to 2020, after serving as VP in Amgen's law department responsible for commercial legal activities in the U.S. and lead commercial lawyer for both the oncology and inflammation business units. Prior to Amgen, she served as General Counsel of SCAN Health Plan, a California Medicare Advantage Plan. Ms. Patton previously served as Chair of the Amgen Foundation and is a board member for the Ethics and Compliance Initiative, the Martin Luther King, Jr. Community Hospital in Los Angeles, a private, nonprofit, safety-net hospital serving South Los Angeles, and the Los Angeles Music Center. Ms. Patton also serves on the board of trustees of Vassar College, Wildwood School in Los Angeles, and the Program on Corporate Compliance and Enforcement at NYU Law School, as well as the National Association for Law Placement Foundation for Law Career Research and Education. Ms. Patton received her undergraduate degree from Vassar College and her J.D. from George Washington University Law School.

Daniel Karp

Job Titles:

Chief Business Development Officer

Daniel leads our global business development team, which includes mergers & acquisitions, licensing, collaborations, alliance management, and integration. Under his leadership, the team evaluates external opportunities and executes business development transactions. These deals drive growth and accelerate Organon's strategy by building the company's pipeline and portfolio. Prior to joining Organon, Daniel served as Executive Vice President, Corporate Development at Biogen. Previously, he held a number of positions of increasing responsibility at Pfizer, including VP, Head of BD for Worldwide Research & Development, and VP, Head of BD for Pfizer Vaccines, Oncology and Consumer Healthcare. Throughout his career, Daniel and his teams have executed M&A and collaboration deals totaling over $80B in potential value. Most importantly, these transactions have brought new drugs, gene therapies, vaccines, devices, and technologies closer to the patients who need them. Earlier in his career, Daniel held roles in healthcare and life sciences strategy consulting. Daniel has a B.S. in biology from Duke University and an M.B.A. from the Wharton School of the University of Pennsylvania. Currently, he serves as Director on the board of Cartesian Growth Corp II and previously served on the board of Cartesian Growth Corp, which combined with Tiedemann Group and Alvarium Investments.